Eli Lilly And Co (NYSE:LLY) is the latest drug maker to join a growing list of companies forced to pause trials on a coronavirus treatment over safety concerns. AstraZeneca plc. (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) have already paused their phase 3 vaccine trials over adverse events.
No Alarm
While the trials' halting means people will have to wait much longer for a vaccine or treatment, vaccine experts maintain there is no cause for alarm. According to Lawrence Gostin, the trials' pausing demonstrates ethical guard rails of vaccine trials are working as they ought to.
The discovery of an adverse event and pausing of trials should reassure people that the final products would be safe for human consumption. In addition, it is not unusual for companies to pause trials of drugs and vaccines briefly to sort out underlying concerns and issues in a bid to enhance safety levels.
In most cases, it is unusual for a clinical trial, be it for a vaccine or a drug, to go through all the trial phases without an adverse being recorded. It is also important to note that some trials are usually paused even though adverse events registered are not the result of the experimental drug or vaccine.
Coronavirus Treatment Outlook
The occurrence of adverse events in clinical trials is always a reminder that scientific research are unpredictable and prone to misfortunes that can result in side effects. However, the detection of such events in the trial phases is important as it provides a leeway for addressing them before such products going into distribution.
Eli Lily has had to pause the trial of its experimental novel treatment for the virus similar to the Regeneron drug that President Donald Trump recently claimed cured him. The company was forced to halt the trials over unnamed safety concerns. AstraZeneca was forced to halt its trials after one of the participants developed a neurological condition. Johnson and Johnson was forced to halt its trials in what it says was a result of an unknown illness in one of the participants.